Fatigue after initiating rivaroxaban for venous thromboembolism

Fatigue after initiating rivaroxaban for venous thromboembolism

Abstract Background Rivaroxaban was the first new oral anticoagulant approved for treatment of venous thromboembolism (VTE). Clinical trials have shown that rivaroxaban is noninferior to conventional anticoagulation for VTE in efficacy and safety. Increased fatigue after the initiation of rivaroxaba...

Full description

Bibliographic Details
Main Authors: Tina Margrethe Karlsvik, Thore Langfeldt Borgenvik, Mirjam Aadalen, Kristin Utne, Eli Førsund, Camilla Tøvik Jørgensen, René Holst, Lars‐Petter Jelsness‐Jørgensen, Waleed Ghanima
Format: Article
Language:English
Published: Elsevier 2020-05-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
anticoagulants
fatigue
pulmonary embolism
rivaroxaban
thrombosis
venous thromboembolism
Online Access:https://doi.org/10.1002/rth2.12312

Internet

https://doi.org/10.1002/rth2.12312

Similar Items